<?xml version="1.0" encoding="iso-8859-1"?>
<frameset>
	<predicate lemma="proliferate">
		<roleset id="proliferate.01" name="" wordnet="1">
			<roles>
				<role n="0" descr="thing becoming abundant				// gene products //
"/>
				<role n="1" descr="situation of becoming abundant
"/>
				<role n="2" descr="location referring to organ, vitro
"/>
			</roles>
			<example src="MEDLINE" no="1">
				<text>
Cancer cells are characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.

</text>
				<arg n="0">Cancer cells
</arg>
				<arg n="1">-
</arg>
				<arg n="2">-
</arg>
				
			</example>
			<example src="MEDLINE" no="*2">
				<text>
These results show that intrasplenically transplanted fetal liver cells proliferate and differentiate into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.

</text>
				<arg n="0">intrasplenically transplanted fetal liver cells 
</arg>
				<arg n="1">-
</arg>
				<arg n="2">-
</arg>
				<fdg>
1	These	this	det:&gt;2	@DN&gt; %&gt;N DET DEM PL
2	results	result	subj:&gt;3	@SUBJ %NH N NOM PL
3	show	show		@+FMAINV %VA V PRES
4	that	that		@CS %CS CS
5	intrasplenically	intrasplenically		@A&gt; %&gt;N &lt;?&gt; A ABS	@SUBJ %NH &lt;?&gt; A ABS	@OBJ %NH &lt;?&gt; A ABS	@I-OBJ %NH &lt;?&gt; A ABS	@ADVL %EH &lt;?&gt; A ABS	@ADVL %EH &lt;?&gt; ADV	@AD-A&gt; %E&gt; &lt;?&gt; ADV
6	transplanted	transplant		@+FMAINV %VA V PAST	@A&gt; %&gt;N A ABS
7	fetal	fetal	attr:&gt;8	@A&gt; %&gt;N A ABS
8	liver	liver	attr:&gt;9	@A&gt; %&gt;N N NOM SG
9	cells	cell		@SUBJ %NH N NOM PL	@OBJ %NH N NOM PL
10	proliferate	proliferate		@+FMAINV %VA V PRES
11	and	and	cc:&gt;10	@CC %CC CC
12	differentiate	differentiate	cc:&gt;10	@+FMAINV %VA V PRES
13	into	into	goa:&gt;12	@ADVL %EH PREP
14	mature	mature	attr:&gt;15	@A&gt; %&gt;N A ABS
15	cells	cell	pcomp:&gt;13	@&lt;P %NH N NOM PL
16	displaying	display	mod:&gt;15	@-FMAINV %VA ING
17	a	a	det:&gt;20	@DN&gt; %&gt;N DET SG
18	GST	gst	attr:&gt;19	@A&gt; %&gt;N ABBR NOM SG
19	expression	expression	attr:&gt;20	@A&gt; %&gt;N N NOM SG
20	pattern	pattern	obj:&gt;16	@OBJ %NH N NOM SG
21	with	with	ha:&gt;16	@ADVL %EH PREP
22	respective	respective	attr:&gt;23	@A&gt; %&gt;N A ABS
23	enzyme	enzyme	attr:&gt;24	@A&gt; %&gt;N N NOM SG
24	activities	activity	pcomp:&gt;21	@&lt;P %NH N NOM PL
25	similar	similar	mod:&gt;24	@&lt;NOM %N&lt; A ABS
26	to	to	mod:&gt;25	@&lt;NOM %N&lt; PREP
27	adult	adult	attr:&gt;28	@A&gt; %&gt;N N NOM SG
28	liver	liver	pcomp:&gt;26	@&lt;P %NH N NOM SG
29	.     .
</fdg>
			</example>
			<example src="MEDLINE" no="3">
				<text>
Our observations illustrate that the human placenta is endowed with the biochemical machinery to proliferate indefinitely throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.

</text>
				<arg n="0">the human placenta
</arg>
				<arg n="1">throughout gestation
</arg>
				<arg n="2">-
</arg>
				<fdg>
1	Our	we	attr:&gt;2	@A&gt; %&gt;N PRON PERS GEN PL1
2	observations	observation	subj:&gt;3	@SUBJ %NH N NOM PL
3	illustrate	illustrate	main:&gt;0	@+FMAINV %VA V PRES
4	that	that	pm:&gt;9	@CS %CS CS
5	the	the	det:&gt;7	@DN&gt; %&gt;N DET
6	human	human	attr:&gt;7	@A&gt; %&gt;N A ABS
7	placenta	placenta	subj:&gt;8	@SUBJ %NH N NOM SG
8	is	be	v-ch:&gt;9	@+FAUXV %AUX V PRES SG3
9	endowed	endow	obj:&gt;3	@-FMAINV %VP EN
10	with	with	phr:&gt;9	@ADVL %EH PREP
11	the	the	det:&gt;13	@DN&gt; %&gt;N DET
12	biochemical	biochemical	attr:&gt;13	@A&gt; %&gt;N A ABS
13	machinery	machinery	pcomp:&gt;10	@&lt;P %NH N NOM SG
14	to	to	pm:&gt;15	@INFMARK&gt; %AUX INFMARK&gt;
15	proliferate	proliferate	mod:&gt;13	@-FMAINV %VA V INF
16	indefinitely	indefinitely	man:&gt;15	@ADVL %EH ADV
17	throughout	throughout	meta:&gt;15	@ADVL %EH PREP
18	gestation	gestation	pcomp:&gt;17	@&lt;P %NH N NOM SG
19	,	,
20	yet	yet	meta:&gt;23	@CS %CS ADV	@ADVL %EH ADV
21	,	,

22	there	there	subj:&gt;23	@F-SUBJ %NH &lt;Ex&gt; ADV
23	are	be		@+FMAINV %VA V PRES
24	intrinsic	intrinsic	attr:&gt;25	@A&gt; %&gt;N A ABS
25	mechanisms	mechanism	comp:&gt;23	@PCOMPL-S %NH N NOM PL
26	that	that	subj:&gt;28	@SUBJ %NH &lt;Rel&gt; PRON
27	effectively	effectively	man:&gt;28	@ADVL %EH ADV
28	circumscribe	circumscribe	mod:&gt;25	@+FMAINV %VA V PRES
29	the	the	det:&gt;30	@DN&gt; %&gt;N DET
30	extent	extent	obj:&gt;28	@OBJ %NH N NOM SG
31	and	and	cc:&gt;30	@CC %CC CC
32	duration	duration	cc:&gt;30	@OBJ %NH N NOM SG
33	of	of	mod:&gt;32	@&lt;NOM-OF %N&lt; PREP
34	trophoblast	trophoblast	attr:&gt;35	@A&gt; %&gt;N N NOM SG
35	proliferation	proliferation	pcomp:&gt;33	@&lt;P %NH N NOM SG
36	.     .
</fdg>
			</example>
			<example src="MEDLINE" no="4">
				<text>
After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells cease to proliferate and undergo apoptosis, causing tumor regression.

</text>
				<arg n="0">the androgen responsive prostate cancer cells 
</arg>
				<arg n="1">-
</arg>
				<arg n="2">-
</arg>
				<fdg>
1	After	after	tmp:&gt;14	@ADVL %EH PREP
2	androgen	androgen	attr:&gt;3	@A&gt; %&gt;N N NOM SG
3	withdrawal	withdrawal	pcomp:&gt;1	@&lt;P %NH N NOM SG
4	and	and	cc:&gt;3	@CC %CC CC
5	antiandrogen	antiandrogen	attr:&gt;6	@A&gt; %&gt;N &lt;?&gt; A ABS
6	treatment	treatment	cc:&gt;3	@&lt;P %NH N NOM SG
7	,	,
8	the	the	det:&gt;13	@DN&gt; %&gt;N DET
9	androgen	androgen	attr:&gt;10	@A&gt; %&gt;N N NOM SG
10	responsive	responsive	attr:&gt;11	@A&gt; %&gt;N A ABS
11	prostate	prostate	attr:&gt;12	@A&gt; %&gt;N A ABS
12	cancer	cancer	attr:&gt;13	@A&gt; %&gt;N N NOM SG
13	cells	cell	subj:&gt;14	@SUBJ %NH N NOM PL
14	cease	cease	main:&gt;0	@+FMAINV %VA V PRES
15	to	to	pm:&gt;16	@INFMARK&gt; %AUX INFMARK&gt;
16	proliferate	proliferate	obj:&gt;14	@-FMAINV %VA V INF
17	and	and	cc:&gt;16	@CC %CC CC
18	undergo	undergo	cc:&gt;16	@-FMAINV %VA V INF
19	apoptosis	apoptosis	comp:&gt;18	@PCOMPL-S %NH N NOM SG
20	,	,
21	causing	cause	ha:&gt;18	@-FMAINV %VA ING
22	tumor	tumor	attr:&gt;23	@A&gt; %&gt;N N NOM SG
23	regression	regression	obj:&gt;21	@OBJ %NH N NOM SG
24	.     .
</fdg>
			</example>
			<example src="EMBO" no="1">
				<text>
Stat5ab-/-peripheral T cells regain the ability to proliferate upon introduction of full-length wild-type Stat5a (Figure 6B).

</text>
				<arg n="0">Stat5ab-/-peripheral T cells
</arg>
				<arg n="1">upon introduction of full-length wild-type Stat5a
</arg>
				<arg n="2">-
</arg>
				<fdg>

1	Stat5ab	stat5ab		@NH %NH &lt;?&gt; N NOM SG
2	-	-
3	/	/	
4	-	-
5	peripheral	peripheral	attr:&gt;6	@A&gt; %&gt;N A ABS
6	T	t	attr:&gt;7	@A&gt; %&gt;N ABBR NOM SG
7	cells	cell	subj:&gt;8	@SUBJ %NH N NOM PL
8	regain	regain	main:&gt;0	@+FMAINV %VA V PRES
9	the	the	det:&gt;10	@DN&gt; %&gt;N DET
10	ability	ability	obj:&gt;8	@OBJ %NH N NOM SG
11	to	to	pm:&gt;12	@INFMARK&gt; %AUX INFMARK&gt;
12	proliferate	proliferate	mod:&gt;10	@-FMAINV %VA V INF
13	upon	upon	ha:&gt;12	@ADVL %EH PREP
14	introduction	introduction	pcomp:&gt;13	@&lt;P %NH N NOM SG
15	of	of	mod:&gt;14	@&lt;NOM-OF %N&lt; PREP
16	full-length	full-length	attr:&gt;17	@A&gt; %&gt;N A ABS
17	wild-type	wild-type	attr:&gt;18	@A&gt; %&gt;N A ABS
18	Stat5a	stat5a	pcomp:&gt;15	@&lt;P %NH &lt;?&gt; N NOM SG
19	(	(
20	Figure	figure	attr:&gt;21	@A&gt; %&gt;N N NOM SG
21	6B	6b		@NH %NH NUM CARD	@APP %NH NUM CARD	@A&gt; %&gt;N NUM CARD
22	)	)
23	.     .
</fdg>
			</example>
			<example src="PNAS" no="1">
				<text>
Adult naive T cells, which are at rest in normal conditions, proliferate strongly when transferred to lymphopenic hosts. 

</text>
				<arg n="0">Adult naive T cells 
</arg>
				<arg n="1">when transferred to lymphopenic hosts 
</arg>
				<arg n="2">-
</arg>
				<fdg>
1	Adult	adult	attr:&gt;2	@A&gt; %&gt;N N NOM SG
2	naive	naive	attr:&gt;3	@A&gt; %&gt;N A ABS
3	T	t	attr:&gt;4	@A&gt; %&gt;N ABBR NOM SG
4	cells	cell	subj:&gt;14	@SUBJ %NH N NOM PL
5	,	,
6	which	which	subj:&gt;7	@SUBJ %NH &lt;Rel&gt; PRON WH NOM
7	are	be	mod:&gt;4	@+FMAINV %VA V PRES
8	at	at	loc:&gt;7	@ADVL %EH PREP
9	rest	rest	pcomp:&gt;8	@&lt;P %NH N NOM SG
10	in	in	mod:&gt;9	@&lt;NOM %N&lt; PREP
11	normal	normal	attr:&gt;12	@A&gt; %&gt;N A ABS
12	conditions	condition	pcomp:&gt;10	@&lt;P %NH N NOM PL
13	,	,
14	proliferate	proliferate	main:&gt;0	@+FMAINV %VA V PRES
15	strongly	strongly	man:&gt;14	@ADVL %EH ADV
16	when	when	tmp:&gt;17	@ADVL %EH ADV WH
17	transferred	transfer	tmp:&gt;14	@-FMAINV %VP EN
18	to	to	ha:&gt;17	@ADVL %EH PREP
19	lymphopenic	lymphopenic	attr:&gt;20	@A&gt; %&gt;N &lt;?&gt; A ABS
20	hosts	host	pcomp:&gt;18	@&lt;P %NH N NOM PL
21	.     .
</fdg>
			</example>
			<example src="PNAS" no="2">
				<text>
HSC continued to proliferate in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.

</text>
				<arg n="0">HSC
</arg>
				<arg n="1">through 8 days of G-CSF treatment 
</arg>
				<arg n="2">in the bone marrow and spleen
</arg>
				<fdg>
1	HSC	hsc	subj:&gt;2	@SUBJ %NH ABBR NOM SG
2	continued	continue	main:&gt;0	@+FMAINV %VA V PAST
3	to	to	pm:&gt;4	@INFMARK&gt; %AUX INFMARK&gt;
4	proliferate	proliferate	obj:&gt;2	@-FMAINV %VA V INF
5	in	in	ha:&gt;4	@ADVL %EH PREP
6	the	the	det:&gt;8	@DN&gt; %&gt;N DET
7	bone	bone	attr:&gt;8	@A&gt; %&gt;N N NOM SG
8	marrow	marrow	pcomp:&gt;5	@&lt;P %NH N NOM SG
9	and	and	cc:&gt;8	@CC %CC CC
10	spleen	spleen	cc:&gt;8	@&lt;P %NH N NOM SG
11	through	through	mod:&gt;10	@&lt;NOM %N&lt; PREP
12	8	8	qn:&gt;13	@QN&gt; %&gt;N NUM CARD
13	days	day	pcomp:&gt;11	@&lt;P %NH N NOM PL
14	of	of	mod:&gt;13	@&lt;NOM-OF %N&lt; PREP
15	G-CSF	g-csf	attr:&gt;16	@A&gt; %&gt;N N NOM SG
16	treatment	treatment	pcomp:&gt;14	@&lt;P %NH N NOM SG
17	,	,
18	but	but		@CC %CC CC
19	HSC	hsc		@SUBJ %NH ABBR NOM SG	@OBJ %NH ABBR NOM SG	@PCOMPL-S %NH ABBR NOM SG	@APP %NH ABBR NOM SG	@&lt;P %NH ABBR NOM SG	@&lt;NOM %N&lt; ABBR NOM SG	@ADVL %EH ABBR NOM SG
20	released	release		@-FMAINV %VP EN
21	into	into	goa:&gt;20	@ADVL %EH PREP
22	the	the	det:&gt;23	@DN&gt; %&gt;N DET
23	blood	blood	pcomp:&gt;21	@&lt;P %NH N NOM SG
24	tended	tend	mod:&gt;23	@-FMAINV %VP EN
25	to	to	pm:&gt;26	@INFMARK&gt; %AUX INFMARK&gt;
26	be	be	cnt:&gt;24	@-FMAINV %VA V INF
27	in	in	ha:&gt;26	@ADVL %EH PREP
28	G0/G1	g0/g1		@QN&gt; %&gt;N &lt;?&gt; NUM CARD
29	phase	phase	pcomp:&gt;27	@&lt;P %NH N NOM SG
30	.     .
</fdg>
			</example>
			<example src="PNAS" no="3">
				<text>
The ability of EBD cells to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.

</text>
				<arg n="0">EBD cells 
</arg>
				<arg n="1">-
</arg>
				<arg n="2">in vivo
</arg>
				<fdg>
1	The	the	det:&gt;2	@DN&gt; %&gt;N DET
2	ability	ability	subj:&gt;9	@SUBJ %NH N NOM SG
3	of	of	mod:&gt;2	@&lt;NOM-OF %N&lt; PREP
4	EBD	ebd	attr:&gt;5	@A&gt; %&gt;N N NOM SG
5	cells	cell	pcomp:&gt;3	@&lt;P %NH N NOM PL
6	to	to	pm:&gt;7	@INFMARK&gt; %AUX INFMARK&gt;
7	proliferate	proliferate	mod:&gt;5	@-FMAINV %VA V INF
8	in vivo	in vivo	obj:&gt;7	@OBJ %NH A ABS
9	was	be	v-ch:&gt;10	@+FAUXV %AUX V PAST
10	examined	examine	main:&gt;0	@-FMAINV %VP EN
11	by	by	agt:&gt;10	@ADVL %EH PREP
12	injection	injection	pcomp:&gt;11	@&lt;P %NH N NOM SG
13	of	of	mod:&gt;12	@&lt;NOM-OF %N&lt; PREP
14	3	3	pcomp:&gt;13	@&lt;P %NH NUM CARD
15	?	?
16	&lt;s&gt;	&lt;s&gt;
1	106	106	main:&gt;0	@NH %NH NUM CARD
2	LVEC	lvec	attr:&gt;3	@A&gt; %&gt;N N NOM SG
3	cells	cell		@NH %NH N NOM PL
4	into	into	mod:&gt;3	@&lt;NOM %N&lt; PREP
5	the	the	det:&gt;7	@DN&gt; %&gt;N DET
6	calf	calf	attr:&gt;7	@A&gt; %&gt;N N NOM SG
7	muscle	muscle	pcomp:&gt;4	@&lt;P %NH N NOM SG
8	of	of	mod:&gt;7	@&lt;NOM-OF %N&lt; PREP
9	3	3	qn:&gt;11	@QN&gt; %&gt;N NUM CARD
10	immunocompromised	immunocompromised	attr:&gt;11	@A&gt; %&gt;N &lt;?&gt; A ABS
11	mice	mouse	pcomp:&gt;8	@&lt;P %NH N NOM PL
12	.     .
</fdg>
			</example>
			<example src="PNAS" no="4">
				<text>
Further, HIV-specific CD4+ T cells of viremic patients could be induced to proliferate in response to HIV antigens when costimulation was provided by anti-CD28 antibody in vitro.

</text>
				<arg n="0">HIV-specific CD4+ T cells of viremic patients 
</arg>
				<arg n="1">when costimulation was provided by anti-CD28 antibody 
</arg>
				<arg n="2">in vitro
</arg>
				<fdg>
1	Further	far	loc:&gt;13	@ADVL %EH ADV CMP
2	,	,
3	HIV-specific	hiv-specific	attr:&gt;4	@A&gt; %&gt;N A ABS
4	CD4	cd4	cc:&gt;6	@A&gt; %&gt;N ABBR NOM SG
5	+	+	cc:&gt;6	@CC %CC CC
6	T	t	attr:&gt;7	@A&gt; %&gt;N ABBR NOM SG
7	cells	cell	subj:&gt;11	@SUBJ %NH N NOM PL
8	of	of	mod:&gt;7	@&lt;NOM-OF %N&lt; PREP
9	viremic	viremic	attr:&gt;10	@A&gt; %&gt;N A ABS
10	patients	patient	pcomp:&gt;8	@&lt;P %NH N NOM PL
11	could	could	v-ch:&gt;12	@+FAUXV %AUX V AUXMOD
12	be	be	v-ch:&gt;13	@-FAUXV %AUX V INF
13	induced	induce	main:&gt;0	@-FMAINV %VP EN
14	to	to	pm:&gt;15	@INFMARK&gt; %AUX INFMARK&gt;
15	proliferate	proliferate	cnt:&gt;13	@-FMAINV %VA V INF
16	in	in	ha:&gt;15	@ADVL %EH PREP
17	response	response	pcomp:&gt;16	@&lt;P %NH N NOM SG
18	to	to	mod:&gt;17	@&lt;NOM %N&lt; PREP
19	HIV	hiv	attr:&gt;20	@A&gt; %&gt;N ABBR NOM SG
20	antigens	antigen	pcomp:&gt;18	@&lt;P %NH N NOM PL
21	when	when	tmp:&gt;24	@ADVL %EH ADV WH
22	costimulation	costimulation	subj:&gt;23	@SUBJ %NH &lt;?&gt; N NOM SG
23	was	be	v-ch:&gt;24	@+FAUXV %AUX V PAST
24	provided	provide	tmp:&gt;15	@-FMAINV %VP EN
25	by	by	ha:&gt;24	@ADVL %EH PREP
26	anti-CD28	anti-cd28		@QN&gt; %&gt;N &lt;?&gt; NUM CARD
27	antibody	antibody		@A&gt; %&gt;N N NOM SG	@&lt;P %NH N NOM SG
28	in vitro	in vitro		@ADVL %EH ADV	@&lt;NOM %N&lt; A ABS
29	.     .
</fdg>
			</example>
			<example src="PNAS" no="5">
				<text>
Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, impairs their capacity to proliferate when exposed to FGF2.

</text>
				<arg n="0">endothelial cells
</arg>
				<arg n="1">when exposed to FGF2
</arg>
				<arg n="2">-
</arg>
				<fdg>
1	Treatment	treatment		@NH %NH N NOM SG	@SUBJ %NH N NOM SG
2	of	of	mod:&gt;1	@&lt;NOM-OF %N&lt; PREP
3	endothelial	endothelial	attr:&gt;4	@A&gt; %&gt;N A ABS
4	cells	cell	pcomp:&gt;2	@&lt;P %NH N NOM PL
5	of	of	mod:&gt;4	@&lt;NOM-OF %N&lt; PREP
6	different	different	attr:&gt;7	@A&gt; %&gt;N A ABS
7	origin	origin	pcomp:&gt;5	@&lt;P %NH N NOM SG
8	with	with	mod:&gt;7	@&lt;NOM %N&lt; PREP
9	the	the	det:&gt;14	@DN&gt; %&gt;N DET
10	ganglioside	ganglioside	attr:&gt;11	@A&gt; %&gt;N &lt;?&gt; N NOM SG
11	biosynthesis	biosynthesis	attr:&gt;12	@A&gt; %&gt;N N NOM SG
12	inhibitors	inhibitor	attr:&gt;13	@A&gt; %&gt;N N NOM PL
13	fumonisin	fumonisin	attr:&gt;14	@A&gt; %&gt;N &lt;?&gt; N NOM SG
14	B1	b1	pcomp:&gt;8	@&lt;P %NH ABBR NOM SG
15	,	,
16	D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol	d-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol		@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@APP %NH N NOM SG	@&lt;P %NH N NOM SG
17	or	or		@CC %CC CC
18	D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl	d-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-hcl		@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@APP %NH N NOM SG	@&lt;P %NH N NOM SG
19	,	,
20	impairs	impair	main:&gt;0	@+FMAINV %VA V PRES SG3
21	their	they	attr:&gt;22	@A&gt; %&gt;N PRON PERS GEN PL3
22	capacity	capacity	obj:&gt;20	@OBJ %NH N NOM SG
23	to	to	pm:&gt;24	@INFMARK&gt; %AUX INFMARK&gt;
24	proliferate	proliferate	mod:&gt;22	@-FMAINV %VA V INF
25	when	when	tmp:&gt;26	@ADVL %EH ADV WH
26	exposed	expose	tmp:&gt;24	@-FMAINV %VP EN
27	to	to	ha:&gt;26	@ADVL %EH PREP
28	FGF2	fgf2	pcomp:&gt;27	@&lt;P %NH N NOM SG
29	.     .
</fdg>
			</example>
		</roleset>
	</predicate>
</frameset>
